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Our study aimed to complete the published data on ARV therapy in Africa by describing the baseline
situation in Rwanda before the launch of a large ARV programme (ESTHER). Prescription habits,
frequency and reasons for treatment interruptions but also antiviral efficay, resistance to ARVs and
genotypic variability of the viruses present in Rwanda were analysed. Among the 233 patients
included in the study, it appeared that a vast majority (91%) were under triple therapy and that half
of them had experienced at least one treatment interruption caused mainly by drug shortage or
financial difficulties. Among 60 blood samples analysed, 26 were in virological failure with a viral
load above 1000 RNA copies/ml and 11 presented major drug resistance mutations.
Finally, virological failure could mainly be explained by the high frequency of treatment
interruptions but also by the emergence of drug resistance mutations. Consequently the major
objective for the ESTHER programme to improve the situation in Rwanda will be to reduce the drug
shortage and facilitate the financial accessibility of the treatments.
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Access to antiretroviral therapy (ART) is increasing in
developing countries. However, published experience with
ART in Africa is limited and results obtained are variable:
several studies [1,2] showed high levels of resistance
whereas other prospective studies showed that excellent
compliance is possible [3,4].
In Rwanda, among 500 000 people living with HIV/AIDS
by the end of 2001 (UNAIDS Report, July 2002, 02-26E,
ISBN 92-1973-18-54), less than 1000 patients were receiv-
ing ART. However, implementation of a large-scale ART
programme, the ESTHER (Ensemble pour une Solidarité
THérapeutique En Réseau) network, started at the Centre
Hospitalier de Kigali (CHK) in October 2002 and aimed to
treat 20 000 patients at six sites, through funding from the
Global Fund against AIDS, TB and Malaria.
The aim of our study was to analyse the baseline
situation in Rwanda (documenting current ART-prescrib-
ing habits, and the frequency of and reasons for treatment
interruptions), before the launch of the ESTHER pro-
gramme and before national treatment recommendations
came into use. We also determined antiviral efficacy,
resistance to antiretrovirals (ARVs) and genotypic varia-
bility of non-B viruses present in Rwanda.
Our study was a cross-sectional analysis of all adult
patients on ART who attended the CHK between April and
June 2002 for treatment follow up or hospitalization. The
study should be representative of the situation regarding
ART in Rwanda in the first half of 2002, as the majority of
patients on ART in Rwanda were followed at the CHK.
Data were retrieved from patient charts and interviews
and included demographic data, HIV-related clinical
history, prior and current ART, treatment interruptions
and their causes.
Biological follow up (CD4 count and viral load) was
centralized at the national reference laboratory but was
hindered by cost of tests and by occasional shortages of
reagents. Consequently, treatment efficacy based on CD4
and viral load changes could not be evaluated because
baseline CD4 counts and viral loads were frequently
missing.
Blood samples from 60 patients on treatment for more
than 3 months were collected and shipped to Luxembourg.
HIV RNA levels were assayed there (Monitor Amplicor
v1.5; Roche Molecular Systems, Branchburg, NJ, USA),
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and viral protease and reverse rranscriptase (RT) sequen-
cing and genotypic resistance testing were performed
with the Trugene HIV-1 sequencing kit (Visible Genetics
Inc., Toronto, Ontario, Canada). Subtyping was performed
using the National Centre for Biotechnology Information
internet site.
A total of 233 patients were included in the 3-month
study period, with a male/female ratio of 0.7, and 84% of
patients being more than 35 years old.
Ninety-one per cent of patients were receiving triple
therapy, 8% bitherapy and 1% monotherapy. The most
commonly used regimens in 2002 were two nucleoside
reverse transcriptase inhibitors (NRTIs) [zidovudine
(ZDV) 1 lamivudine (3TC) or stavudine (d4T) 1 didanosine
(ddI)] in association with one nonnucleoside reverse
transcriptase inhibitor (NNRTI) [87.5% efavirenz (EFV)] or
one protease inhibitor (PI) [12.5% indinavir (IDV)].
At least one treatment interruption had been experienced
by 121 of the 233 patients (52%). The main reasons
revealed by the patients were drug shortage (65 of 121
patients; 54%), financial accessibility (29 of 121 patients;
24%), drug intolerance (12 of 121 patients; 10%) and
doubts about treatment efficacy (15 of 121 patients; 12%).
Among the 60 samples shipped to Luxembourg for
plasma viral load measurements, 26 (43.3%) had a viral
load above 1000 HIV-1 RNA copies/mL and were
considered to be in virological failure.
RT and protease in the 26 patients with viral loads
41000 copies/mL were sequenced, of which 22 sequences
could be analysed for subtyping, natural polymorphisms
and resistance mutations.
The subtype distribution was as follows: 11 subtype A
(50%), eight subtype C (36.4%) and three more complex
strains, with high similarities to subtype A but also with
other circulating recombinant forms such as CRF15 and
CRF01_AE.
Analysis of sequences showed a V179I polymorphism in
the RT gene in six of 22 patients (27.3%) and several
polymorphisms in the protease gene: L10I/V/F (31.8%),
K20R (13.6%), M36I (100%), L63P/T (45.4%) and I93L
(36.4%). The protease I93L polymorphism was present in all
subtype C strains.
Eleven of 26 patients (42.3%) in virological failure
presented major drug resistance mutations. Nine of 11
(82%) showed resistance to at least one drug in their
current regimen. Seven of them (63%) had NRTI-associated
mutations, six (54.5%) had NNRTI-associated mutat-
ions and three (27.3%) had PI-associated mutations
(Table 1).
In summary, most of treated patients were already under
triple therapy in mid-2002.
Of the 233 patients included in the study, 60 had blood
samples shipped to Luxembourg, but only 26 had a
detectable viral load and could be used for resistance
testing. However, despite the limited number of tests for
viral load and drug resistance, it appeared that 43% of the
tested patients were in virological failure. The main reason
for this might be the high rate of treatment interruptions
(52%), as resistance mutations explained only 11 of the 26
treatment failures (42%). Drug resistance rates may be
underestimated as some mutations may have disappeared
during treatment interruptions, but frequencies of resis-
tance mutations according to the drug class are consistent
with phenotypic resistance observed in Uganda [2].
The subtype distribution found here is similar to that
found in our recent study on treatment-naı̈ve patients [5],











Mutations associated with resistance to
NRTIs NNRTIs PIs Resistance
116 C ZDV/3TC/EFV Unknown No K65R* ddI
121 A ZDV/3TC/IDV No No D67Nz, K70Rz, M184V* M46I, V82F* 3TC, ZDV, IDV
122 C d4T/ddI/NFV No No K65R* L90M* ddI, NFV, IDVw
132 A d4T/ddI/IDV ZDV/3TC/EFV No M184V* K103N* 3TC, NVP, EFV
138 C d4T/ddI/IDV ZDV/3TC/d4T/ddI/IDV No M41Lz, D67Nz, T69D*, L90M* ZDV, d4T, ddIw, IDVw
V75A/Vz, T215Yz
145 A ZDV/3TC/EFV No Yes§ K103N* NVP, EFV
146 A ZDV/3TC/EFV No No K70Rz, M184V* 3TC, ZDV
148 Mosaı̈c d4T/ddI/EFV No No P236L* EFVw, DLV
173 C ZDV/3TC/EFV ZDV/IDV No K103N* NVP, EFV
176 C ZDV/3TC/EFV No No K101Qw NNRTIsw
189 A ZDV/3TC/EFV No No M184V* K103N* 3TC, EFV, NVP
*Major mutations; zNRTI-associated mutations (NAMs); wpartial resistance; §treatment interrupted 1 month before blood collection. RT, reverse transcriptase;
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; ZDV, zidovudine; 3TC, lamivudine;
EFV, efavirenz; IDV, indinavir; d4T, stavudine; ddI, didanosine.
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with the majority of samples being subtype A but with an
increasing proportion being subtype C. Further investiga-
tions on the three viral strains that could not be clearly
subtyped would be of interest.
The natural polymorphisms observed in protease are
similar to those previously described in non-B subtypes
[1,6]. Interestingly, the major protease mutation L90 M and
the polymorphism I93L were only present in subtype C
strains. The association between the higher natural poly-
morphism in the protease gene of non-B strains and the
lower possible response to PI regimens is still unclear [6,7].
To conclude, the major causes of virological failure in
this setting seem to be treatment interruptions resulting
from drug shortages and patients’ financial constraints
as most patients paid for their treatment out of their
own pockets.
Standardized prescribing guidelines, uninterrupted pro-
curement of affordable or free drugs and better counselling
should improve these figures in the future. In fact, all
ARV purchases are now centrally managed by the
Centrale d’Achat des Medicaments Essentiels du Rwanda
(CAMERWA) Central Pharmacy and major programmes
have been set up to purchase large amounts of ARV in
advance, assuring a security stock of ARV in the country.
Moreover, a group of experts co-ordinated by the National
Programme against AIDS produced a national ARV usage
guide in the middle of 2002.
Today, the ESTHER program has been implemented and
the situation has already improved: treatments have
become free for the majority of patients, there are no
longer any drug shortages, patient follow up is now
standardized and data are collected in a computerized
database. Evaluation of the ESTHER programme is ongoing
and results will be published soon.
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